Consolidated Results First Quarter Ended June 30, 2012

- 1. Overview
- 2. Financial Position
- 3. Segment Information

July 31, 2012 Ajinomoto Co., Inc.

JINOMOTO 1. (1) Overview of Results

								(¥ Billion
			AprJune	AprJune	YoY C	20000	FY2012	Progress
			2012	2011	101 C	nange	(Forecast)	
			(A)		Amount	%	(B)	A/B
Net sales			296.7	296.4	0.3	0%	1,221.0	24%
Domestic	Food	Products	109.7	105.5	4.2	4%	411.0	27%
Oversea	s Food	d Products	58.0	57.5	0.5	1%	254.0	23%
Bioscien	Bioscience Products &		49.8	51.9	-2.1	-4%	215.0	23%
Fine Che	micals	3	43.0	51.9	-2.1	-4 70	215.0	237
Pharmac	eutica	ls	18.1	19.6	-1.4	-7%	76.0	24%
Business	Tie-L	Jps	43.7	44.4	-0.7	-2%	189.0	23%
Other Bu	ısines	s	17.4	17.6	-0.2	-1%	76.0	23%
Operating in	ncome		19.3	21.7	-2.4	-11%	73.5	26%
Domestic	Food	Products	9.0	10.5	-1.5	-14%	32.6	28%
Oversea	s Food	d Products	5.2	6.0	-0.8	-14%	23.0	23%
Bioscien	ce Pro	ducts &	4.4	3.6	0.8	22%	14.9	29%
Fine Che	micals	6	4.4	3.6	0.0	22 /0	14.5	29 /
Pharmac	eutica	ls	0.7	1.4	-0.7	-50%	2.3	31%
Business	Tie-L	Jps	0.4	0.4	-0.0	-3%	1.6	23%
Other Bu	sines	s	-0.4	-0.3	-0.1	38%	-0.9	42%
Ordinary ind	come		20.9	22.6	-1.7	-8%	76.5	27%
Net income			10.0	13.9	-3.9	-28%	44.0	23%
Exchange ra	ate	JPY/USD	80.18	81.71			80.0	
		JPY/EUR	102.84	117.38			105.0	
<reference></reference>	>							(¥ Billion
			AprJune	AprJune	YoY C	hange	FY2012	Progress
			2012	2011	Amount	%	(Forecast)	
Net sales								
Feed-Use /	Amino <i>A</i>	Acids	23.3	21.4	1.9	9%	93.9	25%
Others		273.5	275.0	-1.5	-1%	1,127.1	24%	
Operating inco		N a : al a	0.0	0.7	ادير	000/	10.5	000
Feed-Use /	Amino A	ACIDS	3.8		1.1	39%	10.5	36%
Others			15.5	19.0	-3.5	-18%	63.0	25%



1.(2) Comments on Results for the First Three Months of FY2012

Net sales was essentially the same as in the first three months of the previous fiscal year despite the impact of exchange rates. Operating income decreased because of lower operating income in every segment except Bioscience Products & Fine Chemicals.

Net sales / Operating income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2012	2011	Amount	%	Forecast	
Net sales	296.7	296.4	0.3	0%	1,221.0	24%
Cost of sales	194.7	195.5	-0.8	0%	•	•
SG&A	82.7	79.2	3.5	4%	•	-
Operating income	19.3	21.7	-2.4	-11%	73.5	26%

1. Impact of Exchange rate for currency translation

exchange rate

(YoY)

Sales -¥8.8 billion; operating income -¥1.3 billion

Exchange rate for trade of main overseas subsidiaries

Sales approx. ¥1.5 billion; operating income approx. ¥1.0 billion

2. Impact of raw material & fuel prices (YoY) Fermentation raw materials and fuel prices approx. -\(\frac{4}{2}\)1.0 billion Domestic food products raw materials approx. -\(\frac{4}{2}\)0.1 billion

3. Cost reductions (YoY)

Domestic food products approx. ¥0.5 billion Pharmaceuticals approx. ¥0.5 billion





1. (3) Comments on Results for the First Three Months of FY2012

Ordinary income

(¥ Billion)

	AprJune	AprJune	Change		Full-year	Progress
	2012	2011	Amount	%	Forecast	
Non-operating income (net)	1.6	1.0	0.6	65%	3.0	
Ordinary income	20.9	22.6	-1.8	-8%	76.5	27%

* None


Net income

	AprJune	AprJune	Cha	nge	Full-year	Progress
	2012	2011	Amount	%	Forecast	
Extraordinary gains	0.8	0.4	0.4	116%	-	-
Extraordinary losses	3.0	1.3	1.7	137%		-
Income taxes etc.	7.0	6.3	0.6	10%	-	-
Minority interests	1.7	1.5	0.2	14%	-	-
Net income	10.0	13.9	-3.9	-28%	44.0	23%

- * Gain on sale of stock of affiliates ¥0.5 billion (¥0.5 billion increase YoY)
- * Loss on devaluation of securities ¥2.4 billion (¥2.3 billion increase YoY)
- * Loss from natural disaster ¥0.0 billion (¥0.8 billion decrease YoY)



JINOMOTO. 2. Financial Position



Mar. 31, 2012: Total assets 1,097.1



¥44.4 billion decrease in total assets from March 31, 2012:

- * Decrease in cash and deposits due to share repurchase
- * Decrease due to translation of overseas subsidiaries' balance sheets into yen

Cash Flow

(¥ Billion)

	June 2012	June 2011	Change
1. CF from operating activities	14.1	8.6	5.5
2. CF from investing activities	-16.3	-6.6	-9.6
3. CF from financing activities	-30.8	-21.9	-9.0
4. Cash and cash equivalents	107.4	111.7	-4.3
FCF(1+2)	-2.2	2.0	-4.2

*Cash out is shown with -.

Capital expenditures	16.4	10.8	5.6
Depreciation and amortization	10.4	10.8	-0.4

Interest-bearing Debt


(¥ Billion)

<Reference>

June 2012	Mar. 2012	Change	June 2011
132.8	130.0	2.8	136.9



3. (1) Change by Business Segment



JINOMOTO. 3. (2) Domestic Food Products

		AprJune 2012	Full-year Forecast	Progress	AprJune 2011	Change	
Net sales		109.7	411.0	27%	105.5	4.2	
	Seasonings & processed foods	53.9	-	-	52.3	1.7	*
	Frozen foods	28.2	-	-	26.8	1.4	*2
	Beverages ("Calpis")	27.6	-	-	26.4	1.2	*3
Op	erating income	9.0	32.6	28%	10.5	-1.5	 *∠
	Frozen foods	2.4	-	-	2.1	0.3	
	Beverages ("Calpis")	1.9	-	-	2.7	-0.8	1
	Shared companywide expenses	-2.8	-8.1	34%	-2.6	-0.2	

^{*1} Increase in sales due to rebound from lower sales of certain products in the previous fiscal year that resulted from the Great East Japan Earthquake and firm sales of home-use products.

^{*4} Decrease in income due to higher beverage selling expenses and rebound from reduced sales promotion expenses for seasonings and processed food products, etc. in the previous year resulting from decrease in post-earthquake sales promotions, despite increased income from frozen food products.



^{*2} Sales of products for home-use and for restaurant and institutional-use increased.

^{*3} Increase in sales due to growth in sales of ready-to-drink beverages, functional foods and drinks, and reformulated concentrated beverages.

JINOMOTO. 3. (3) Overseas Food Products

(¥ Billion)

		AprJune 2012	Full-year Forecast	Progress	AprJune 2011	Change	
Ne	t sales	58.0	254.0	23%	57.5	0.5	
	Consumer foods	46.9	206.5	23%	45.4	1.4	* /
	Umami seasonings for processed food mfrs.	11.1	47.5	23%	12.1	-1.0	*2
Op	erating income	5.2	23.0	23%	6.0	-0.8	*(
	Shared companywide expenses	-2.1	-7.9	26%	-1.9	-0.2	

[Effect of currency translation] Net sales -¥4.4 billion; operating income -¥0.7 billion

Reference: Consumer foods +¥0.4 billion; umami seasonings for processed food mfrs. -¥0.7 billion



^{*1} Sales increased due to higher sales volume and changes in unit price, etc. despite negative effect of currency translation.

^{*2} Decrease in sales due to negative effect of currency translation and lower sales volume of MSG, etc.

^{*3} Income decreased due to lower sales prices of nucleotides in umami seasonings for processed food mfrs. despite an increase in income from consumer foods that offset the effect of currency translation.

JINOMOTO 3. (4) Bioscience Products & Fine Chemicals

(¥ Billion)

		AprJune 2012	Full-year Forecast	Progress	AprJune 2011	Change
Ne	t sales	49.8	215.0	23%	51.9	-2.1
	Feed-use amino acids	23.3	93.9	25%	21.4	1.9
	Amino acids	15.4	-	-	18.2	-2.8
	Specialty chemicals	10.0	-	-	10.9	-0.9
Op	erating income	4.4	14.9	29%	3.6	0.8
	Feed-use amino acids	3.8	10.5	36%	2.7	1.1
	Amino acids	1.0	-	-	0.7	0.3
	Specialty chemicals	1.8	-	-	2.5	-0.7
	Shared companywide expenses	-1.5	-5.7	27%	-1.5	-0.0

[Effect of currency translation] Net sales -¥4.2 billion; operating income -¥0.5 billion

- *1 Increase mainly due to higher sales volume of Lysine, etc.
- *2 Amino acids for pharmaceuticals and foods -¥0.3 billion due to negative effect of currency translation, etc. Pharmaceutical fine chemicals -¥1.2 billion and sweeteners -¥1.2 billion due to decrease in sales volume and negative effect of currency translation.
- *3 Sales of cosmetics and cosmetic ingredients and chemicals decreased. Sales of electronics materials decreased slightly year on year because of downturn in shipments for PCs, etc.
- *4 Income increased because feed-use amino acids, amino acids, etc. offset decrease in income of specialty chemicals, negative effect of currency translation, etc.
 - Reference: Within amino acids, amino acids for pharmaceuticals and foods +¥0.7 billion; pharmaceutical fine chemicals -¥0.5 billion; sweeteners +¥0.1 billion



JINOMOTO₈ 3. (5) Pharmaceuticals

(¥ Billion)

		AprJune 2012	Full-year Forecast	Progress	AprJune 2011	Change	
Ne	t sales	18.1	76.0	24%	19.6	-1.4	*1
Op	perating income	0.7	2.3	31%	1.4	-0.7	*2
	Shared companywide expenses	-0.5	-2.0	27%	-0.5	-0.0	

^{*1} Sales of self-distributed products decreased due to the impact of NHI drug price revisions. Sales of products sold through business tie-ups also decreased due to the impact of NHI drug price revisions and growth in sales of competing products.

Sales based on AJINOMOTO PHARMACEUTICALS CO., LTD. estimated drug prices (% = YoY change):

 LIVACT
 ¥3.9 billion (-1%)
 ATELEC
 ¥3.9 billion (-9%)

 ELENTAL
 ¥2.0 billion (+1%)
 ACTONEL
 ¥3.1 billion (-17%)

 CARBOSTAR
 ¥1.6 billion (+28%)
 FASTIC
 ¥0.7 billion (-37%)

SOLITA-T ¥1.0 billion (-9%)

*2 Decrease in income as a result of decrease in sales due to the impact of NHI drug price revisions, etc.



3. (6) Business Tie-Ups and Other Business

(¥ Billion)

Bu	siness Tie-Ups	AprJune 2012	Full-year Forecast	Progress	AprJune 2011	Change	
Net sales		43.7	189.0	23%	44.4	-0.7	
	Edible oils	10.3	-	-	10.8	-0.5	*1
	Coffee products	33.4	-	-	33.6	-0.2	*2
Op	erating income	0.4	1.6	23%	0.4	-0.0	
	Shared companywide expenses	-0.1	-0.5	25%	-0.1	-0.0	

^{*1} Decrease in sales due to lower unit prices, etc., despite higher sales volume.

Other Business		AprJune 2012 Full-year Forecast		Progress	AprJune 2011	Change	
Ne	t sales	17.4	76.0	23%	17.6	-0.2	*1
Operating income		-0.4	-0.9	42%	-0.3	-0.1	*2
	Shared companywide expenses	-0.6	-2.3	27%	-0.6	-0.0	

^{*1} Decrease in sales because of decrease in orders in the engineering business, etc., despite higher sales in wellness business.

^{*2} Decrease in sales due to lower sales of instant coffee, etc.

^{*2} Decrease in income due to higher selling expenses in wellness business, etc.



3. (7) Net Sales by Business & Geographical Area


Upper row: Apr.-June 2012; lower row: Apr.-June 2011.

Figures in parentheses represent YoY change.

	Japan		Asia		Americas		Europe		Total	
Domestic Food	105.9	(4.1)	1.5	(0.0)	1.9	(0.1)	0.4	(-0.1)	109.7	(4.2)
Products	101.8		1.5		1.8		0.4		105.5	
Overseas Food	2.4	(-0.0)	38.9	(1.9)	10.7	(-1.4)	6.0	(0.1)	58.0	(0.5)
Products	2.4		37.0		12.1		5.9		57.5	
Bioscience Products	15.2	(8.0-)	3.8	(0.1)	15.0	(-0.3)	15.7	(-1.0)	49.8	(-2.1)
& Fine Chemicals	16.0		3.8		15.3		16.8		51.9	
Pharmaceuticals	18.1	(-1.4)							18.1	(-1.4)
	19.6								19.6	
Business Tie-Ups	43.7	(-0.7)							43.7	(-0.7)
	44.4								44.4	
Other Business	15.4	(-0.3)	2.0	(0.1)	0.0	(0.0)			17.4	(-0.2)
	15.7		1.9		0.0				17.6	
Total	200.8	(1.0)	46.2	(2.0)	27.6	(-1.6)	22.1	(-1.0)	296.7	(0.3)
i Ulai	199.8		44.2		29.2		23.1		296.4	. ,

JINOMOTO_®

3. (8) Operating Income by Business & Geographical Area





3. (9) Comments on Operating Income by Business & Geographical Area

Apr.–June 2012 Change Compared with Same Period of Previous Year

(¥ Billion)

1. Overseas Food Products

[YoY change]

Japan -¥0.3; Asia +¥0.2; Americas +¥0.6; Europe -¥0.7; Other* -¥0.7; Total -¥0.8

Americas: Increase due to positive effect of currency translation in South America, etc.

Europe: Decrease due to negative effect of currency translation and decrease in sales

of umami seasonings for processed food mfrs, etc.

2. Bioscience Products & Fine Chemicals

[YoY change]

Japan +¥0.9; Asia +¥0.2; Americas +¥0.5; Europe -¥0.8; Other* +¥0.0; Total +¥0.8

Japan: Increase due to amino acids, etc.


Europe: Decrease due to amino acids etc.

^{*} Unrealized gains and losses not reflected in any geographical area, and shared companywide expenses.



✓JINOMOTO. [Reference] Feed-Use Lysine Market Price and CBOT Spread* Trend

*The spread is the price difference between soybean meal and corn on the Chicago Board Of Trade (CBOT).



- ➤ Forward-looking statements, such as business performance forecasts, made in these materials are based on management's estimates, assumptions and projections at the time of publication and do not represent a commitment from Ajinomoto Co., Inc. that they will be achieved. A number of factors could cause actual results to differ materially from expectations.
- ➤ Unaudited figures are included in these materials for reference.
- >Amounts presented in these materials are rounded off.